Biglycan: A promising new therapeutic for neuromuscular and musculoskeletal diseases

Current Opinion in Genetics and Development

Volumn 22, Issue 4, 2012, Pages 398-400

  Young, Marian F ^a   Fallon, Justin R ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; TRANSFORMING GROWTH FACTOR BETA;

BIGLYCAN GENE; BONE REGENERATION; BONE REMODELING; BONE TURNOVER; COMPLEX FORMATION; DRUG EFFECT; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; MUSCULAR DYSTROPHY; MUSCULOSKELETAL DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; NOTE; OSSIFICATION; OSTEOARTHRITIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; WNT SIGNALING PATHWAY;

ANIMALS; BIGLYCAN; EXTRACELLULAR MATRIX; HUMANS; MUSCULOSKELETAL DISEASES; NEUROMUSCULAR DISEASES;

EID: 84865579177     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2012.07.008     Document Type: Note

References (11)

1. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., Bonadio J., Boskey A., Heegaard A.M., Sommer B., et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 1998, 20:78-82.
2. Chen X.D., Fisher L.W., Robey P.G., Young M.F. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J 2004, 18:948-958.
3. Embree M.C., Kilts T.M., Ono M., Inkson C.A., Syed-Picard F., Karsdal M.A., Oldberg A., Bi Y., Young M.F. Biglycan and fibromodulin have essential roles in regulating chondrogenesis and extracellular matrix turnover in temporomandibular joint osteoarthritis. Am J Pathol 2010, 176:812-826.
4. Bi Y., Ehirchiou D., Kilts T.M., Inkson C.A., Embree M.C., Sonoyama W., Li L., Leet A.I., Seo B.M., Zhang L., et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007, 13:1219-1227.
5. Berendsen A.D., Fisher L.W., Kilts T.M., Owens R.T., Robey P.G., Gutkind J.S., Young M.F. Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc Natl Acad Sci USA 2011, 108:17022-17027.
6. Bowe M.A., Mendis D.B., Fallon J.R. The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. J Cell Biol 2000, 148:801-810.
7. Rafii M.S., Hagiwara H., Mercado M.L., Seo N.S., Xu T., Dugan T., Owens R.T., Hook M., McQuillan D.J., Young M.F., Fallon J.R. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol 2006, 209:439-447.
8. Mercado M.L., Amenta A.R., Hagiwara H., Rafii M.S., Lechner B.E., Owens R.T., McQuillan D.J., Froehner S.C., Fallon J.R. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 2006, 20:1724-1726.
9. Amenta A.R., Yilmaz A., Bogdanovich S., McKechnie B.A., Abedi M., Khurana T.S., Fallon J.R. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 2011, 108:762-767.
10. Moreth K., Brodbeck R., Babelova A., Gretz N., Spieker T., Zeng-Brouwers J., Pfeilschifter J., Young M.F., Schaefer R.M., Schaefer L. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 2010, 120:4251-4272.
11. Amenta A.R., Creely H.E., Mercado M.L., Hagiwara H., McKechnie B.A., Lechner B.E., Rossi S.G., Wang Q., Owens R.T., Marrero E., et al. Biglycan is an extracellular MuSK binding protein important for synapse stability. J Neurosci 2012, 32:2324-2334.